Literature DB >> 32016064

Erlotinib plus bevacizumab for EGFR-mutant advanced non-squamous non-small-cell lung cancer patients: ready for first-line?

Helen Adderley1, Christoph Jakob Ackermann1, Raffaele Califano1,2,3.   

Abstract

Entities:  

Year:  2019        PMID： 32016064      PMCID： PMC6976499          DOI： 10.21037/atm.2019.09.116

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  18 in total

Review 1.  EGFR-TKI resistance in NSCLC patients: mechanisms and strategies.

Authors:  Yuxin Lin; Xian Wang; Hongchuan Jin
Journal:  Am J Cancer Res       Date:  2014-09-06       Impact factor: 6.166

2.  A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.

Authors:  A Lisberg; A Cummings; J W Goldman; K Bornazyan; N Reese; T Wang; P Coluzzi; B Ledezma; M Mendenhall; J Hunt; B Wolf; B Jones; J Madrigal; J Horton; M Spiegel; J Carroll; J Gukasyan; T Williams; L Sauer; C Wells; A Hardy; P Linares; C Lim; L Ma; C Adame; Edward B Garon
Journal:  J Thorac Oncol       Date:  2018-06-01       Impact factor: 15.609

3.  Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.

Authors:  Martin Reck; Joachim von Pawel; Petr Zatloukal; Rodryg Ramlau; Vera Gorbounova; Vera Hirsh; Natasha Leighl; Jörg Mezger; Venice Archer; Nicola Moore; Christian Manegold
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544

4.  Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.

Authors:  Takashi Seto; Terufumi Kato; Makoto Nishio; Koichi Goto; Shinji Atagi; Yukio Hosomi; Noboru Yamamoto; Toyoaki Hida; Makoto Maemondo; Kazuhiko Nakagawa; Seisuke Nagase; Isamu Okamoto; Takeharu Yamanaka; Kosei Tajima; Ryosuke Harada; Masahiro Fukuoka; Nobuyuki Yamamoto
Journal:  Lancet Oncol       Date:  2014-08-27       Impact factor: 41.316

5.  Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial.

Authors:  Martin Reck; Tony S K Mok; Makoto Nishio; Robert M Jotte; Federico Cappuzzo; Francisco Orlandi; Daniil Stroyakovskiy; Naoyuki Nogami; Delvys Rodríguez-Abreu; Denis Moro-Sibilot; Christian A Thomas; Fabrice Barlesi; Gene Finley; Anthony Lee; Shelley Coleman; Yu Deng; Marcin Kowanetz; Geetha Shankar; Wei Lin; Mark A Socinski
Journal:  Lancet Respir Med       Date:  2019-03-25       Impact factor: 30.700

6.  Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial.

Authors:  Haruhiro Saito; Tatsuro Fukuhara; Naoki Furuya; Kana Watanabe; Shunichi Sugawara; Shunichiro Iwasawa; Yoshio Tsunezuka; Ou Yamaguchi; Morihito Okada; Kozo Yoshimori; Ichiro Nakachi; Akihiko Gemma; Koichi Azuma; Futoshi Kurimoto; Yukari Tsubata; Yuka Fujita; Hiromi Nagashima; Gyo Asai; Satoshi Watanabe; Masaki Miyazaki; Koichi Hagiwara; Toshihiro Nukiwa; Satoshi Morita; Kunihiko Kobayashi; Makoto Maemondo
Journal:  Lancet Oncol       Date:  2019-04-08       Impact factor: 41.316

7.  Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L).

Authors:  Hiroaki Akamatsu; Shunsuke Teraoka; Satoshi Morita; Nobuyuki Katakami; Motoko Tachihara; Haruko Daga; Nobuyuki Yamamoto; Kazuhiko Nakagawa
Journal:  Clin Lung Cancer       Date:  2019-03-19       Impact factor: 4.785

8.  A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER).

Authors:  Yuankai Shi; Joseph Siu-Kie Au; Sumitra Thongprasert; Sankar Srinivasan; Chun-Ming Tsai; Mai Trong Khoa; Karin Heeroma; Yohji Itoh; Gerardo Cornelio; Pan-Chyr Yang
Journal:  J Thorac Oncol       Date:  2014-02       Impact factor: 15.609

9.  Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.

Authors:  Jean-Charles Soria; Yuichiro Ohe; Johan Vansteenkiste; Thanyanan Reungwetwattana; Busyamas Chewaskulyong; Ki Hyeong Lee; Arunee Dechaphunkul; Fumio Imamura; Naoyuki Nogami; Takayasu Kurata; Isamu Okamoto; Caicun Zhou; Byoung Chul Cho; Ying Cheng; Eun Kyung Cho; Pei Jye Voon; David Planchard; Wu-Chou Su; Jhanelle E Gray; Siow-Ming Lee; Rachel Hodge; Marcelo Marotti; Yuri Rukazenkov; Suresh S Ramalingam
Journal:  N Engl J Med       Date:  2017-11-18       Impact factor: 91.245

10.  Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer.

Authors:  Tony S Mok; Yi-Long Wu; Myung-Ju Ahn; Marina C Garassino; Hye R Kim; Suresh S Ramalingam; Frances A Shepherd; Yong He; Hiroaki Akamatsu; Willemijn S M E Theelen; Chee K Lee; Martin Sebastian; Alison Templeton; Helen Mann; Marcelo Marotti; Serban Ghiorghiu; Vassiliki A Papadimitrakopoulou
Journal:  N Engl J Med       Date:  2016-12-06       Impact factor: 91.245
View more
  2 in total

1.  Rational Application of First-Line EGFR-TKIs Combined with Antiangiogenic Inhibitors in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis.

Authors:  Jie-Tao Ma; Yi-Jia Guo; Jun Song; Li Sun; Shu-Ling Zhang; Le-Tian Huang; Wei Jing; Jian-Zhu Zhao; Cheng-Bo Han
Journal:  Biomed Res Int       Date:  2021-01-28       Impact factor: 3.411

2.  Potential of combination therapy in EGFR mutated lung cancer.

Authors:  Makoto Maemondo
Journal:  Ann Transl Med       Date:  2020-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.